Cumberland Pharmaceuticals Inc (CPIX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cumberland Pharmaceuticals Inc (CPIX) has a cash flow conversion efficiency ratio of 0.007x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($187.18K) by net assets ($25.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cumberland Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Cumberland Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Cumberland Pharmaceuticals Inc (CPIX) total liabilities for a breakdown of total debt and financial obligations.
Cumberland Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cumberland Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Flanigans Enterprises Inc
NYSE MKT:BDL
|
0.062x |
|
Monalisa
KO:012690
|
0.021x |
|
Namhwa Industrial Co. Ltd
KQ:111710
|
-0.006x |
|
Mesa Air Group Inc
NASDAQ:MESA
|
0.054x |
|
Eltek Ltd
NASDAQ:ELTK
|
0.044x |
|
Theralase Technologies Inc.
V:TLT
|
-0.629x |
|
Scilex Holding Company
NASDAQ:SCLX
|
-0.046x |
|
Anson Resources Ltd
AU:ASN
|
-0.082x |
Annual Cash Flow Conversion Efficiency for Cumberland Pharmaceuticals Inc (2005–2024)
The table below shows the annual cash flow conversion efficiency of Cumberland Pharmaceuticals Inc from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see Cumberland Pharmaceuticals Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $22.55 Million | $-612.19K | -0.027x | -113.04% |
| 2023-12-31 | $29.26 Million | $6.09 Million | 0.208x | -11.37% |
| 2022-12-31 | $35.97 Million | $8.45 Million | 0.235x | +57.84% |
| 2021-12-31 | $42.60 Million | $6.34 Million | 0.149x | +28.87% |
| 2020-12-31 | $46.87 Million | $5.42 Million | 0.116x | +93.09% |
| 2019-12-31 | $51.09 Million | $3.06 Million | 0.060x | +6.81% |
| 2018-12-31 | $55.57 Million | $3.11 Million | 0.056x | +742.00% |
| 2017-12-31 | $63.92 Million | $-557.71K | -0.009x | -212.03% |
| 2016-12-31 | $73.12 Million | $569.48K | 0.008x | -89.82% |
| 2015-12-31 | $76.82 Million | $5.88 Million | 0.077x | -7.70% |
| 2014-12-31 | $80.75 Million | $6.69 Million | 0.083x | +780.86% |
| 2013-12-31 | $79.29 Million | $746.13K | 0.009x | -88.72% |
| 2012-12-31 | $85.57 Million | $7.14 Million | 0.083x | -20.81% |
| 2011-12-31 | $82.84 Million | $8.72 Million | 0.105x | +2260.53% |
| 2010-12-31 | $77.72 Million | $346.66K | 0.004x | -20.45% |
| 2009-12-31 | $72.22 Million | $404.97K | 0.006x | -98.46% |
| 2008-12-31 | $17.55 Million | $6.40 Million | 0.364x | -29.26% |
| 2007-12-31 | $16.75 Million | $8.63 Million | 0.515x | +164.95% |
| 2006-12-31 | $11.13 Million | $2.16 Million | 0.194x | -49.83% |
| 2005-12-31 | $6.23 Million | $2.42 Million | 0.388x | -- |
About Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fe… Read more